Methods for preparing carriers, carriers and their applications
By preparing a mixture of protein raw materials, proteases, metal ion crosslinking agents, and nucleotide derivatives and incubating them together, a nanotube-structured carrier was obtained. This process overcomes the shortcomings of existing mitochondrial targeted delivery systems, achieving precise and efficient delivery of nicotinamide mononucleotides and enhancing the therapeutic effect of mitochondrial dysfunction diseases.
Patent Information
- Application Number
- CN202510621041.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing mitochondrial targeted delivery systems have significant shortcomings in terms of NMN targeting, delivery efficiency, and NAD+ conversion efficiency, making it difficult to achieve precise delivery and long-term safety.
By mixing and incubating protein raw materials, proteases, metal ion crosslinking agents, and nucleotide derivatives, a nanotube structure carrier with self-assembly capability was prepared. This carrier can precisely target mitochondria and efficiently deliver nicotinamide mononucleotides, making it suitable for encapsulating a variety of bioactive substances.
It achieves precise targeting, efficient delivery, and good biocompatibility of the carrier, making it suitable for cosmetics, health products, or pharmaceuticals, and enhancing the therapeutic effect of mitochondrial dysfunction diseases.
Smart Images

Figure HDA0005402499290000011 
Figure HDA0005402499290000021 
Figure HDA0005402499290000031
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to methods for preparing vectors, vectors, and their applications. Background Technology
[0002] Mitochondria, as the core of cellular energy metabolism, are closely related to the occurrence and development of various diseases. Achieving efficient mitochondrial-targeted delivery of nutrients is of great significance for correcting mitochondrial dysfunction and improving treatment efficacy. Currently, mitochondrial-targeted delivery strategies mainly include chemical modification and carrier-mediated delivery, but there are still shortcomings in terms of precise delivery, long-term safety, and stability. For example, chemical modification using TPP (triphenylphosphine) utilizes its positive charge to deliver nutrients based on the mitochondrial membrane potential difference, but its excessive charge may lead to decreased membrane stability and cytotoxicity, thus limiting long-term application. In addition, there are targeted peptide modifications (such as cell-penetrating peptides containing mitochondrial localization sequences) that achieve delivery by recognizing mitochondrial receptors through peptide chains, but they are susceptible to protease degradation, and the coupling process may destroy the bioactivity of nutrients. Furthermore, liposomes such as MITOporter can target nutrients through functional groups, but differences in carrier particle size and metabolic residues may lead to uneven efficiency or accumulation in vivo.
[0003] Among many nutrients, nicotinamide mononucleotide (NMN) is a nucleotide derivative that acts as a nicotinamide adenine dinucleotide (NAD) + As a precursor to NMN, it plays a crucial role in cellular energy metabolism and redox reactions. NMN possesses the potential for anti-aging, DNA damage repair, and improved mitochondrial function, and is believed to have protective effects against various age-related diseases. Furthermore, NMN is also being applied in areas such as enhancing cognitive function, cardiovascular health, and metabolic regulation. Currently, some studies have attempted to deliver NMN via liposomes or nanoparticles, but existing delivery systems face challenges in mitochondrial targeting, delivery efficiency, and NAD+. + There are still significant shortcomings in terms of conversion efficiency.
[0004] Therefore, it is necessary to develop a method that can precisely target mitochondria and efficiently deliver NMN and NAD. + A high-efficiency delivery system that can also deliver other bioactive ingredients is of great significance for fully realizing the potential of NMN in anti-aging and the treatment of mitochondrial dysfunction. Summary of the Invention
[0005] This invention aims to at least partially address one of the technical problems existing in the prior art. To this end, this invention provides a method for preparing a carrier, the carrier itself, and its applications. The method for preparing the carrier involves mixing protein raw materials, a protease, a metal ion cross-linking agent, and a nucleotide derivative (such as nicotinamide mononucleotide) and incubating them to obtain the carrier. This method is characterized by its simplicity, ease of operation, and suitability for large-scale production. The carrier prepared by this method can precisely target mitochondria, efficiently deliver nucleotide derivatives (such as nicotinamide mononucleotide), exhibit good biocompatibility and stability, and is suitable for encapsulating various bioactive substances, showing broad application prospects.
[0006] In a first aspect, the present invention provides a method for preparing a carrier. According to an embodiment of the present invention, the method includes: S1: mixing protein raw materials, protease, metal ion cross-linking agent, and nucleotide derivative to obtain a mixed system; S2: incubating the mixed system, collecting the precipitate, and obtaining the carrier. According to the method of the present invention, the carrier is obtained by mixing protein raw materials, protease, metal ion cross-linking agent, and nucleotide derivative (such as nicotinamide mononucleotide) and incubating them. This method has the advantages of simple preparation method, convenient operation, and easy large-scale production. The carrier prepared by this method can accurately target mitochondria, efficiently deliver nucleotide derivatives (such as nicotinamide mononucleotide), and has good biocompatibility and stability. It is also suitable for encapsulating various bioactive substances and has broad application prospects.
[0007] According to embodiments of the present invention, the above-described method for preparing the carrier may further include the following additional technical features:
[0008] According to embodiments of the present invention, the protein raw material comprises proteins with self-assembly capabilities.
[0009] According to embodiments of the present invention, the protein raw materials include one or more of α-lactalbumin raw materials, bovine serum albumin raw materials, soy protein raw materials, ovalbumin raw materials, ovalbumin raw materials, and lysozyme raw materials.
[0010] According to embodiments of the present invention, the protease includes one or more of Bacillus licheniformis protease, Bacillus subtilis protease A, trypsin, pepsin, and papain.
[0011] According to embodiments of the present invention, the metal ion crosslinking agent includes one or more of calcium ions, manganese ions, magnesium ions, nickel ions, cadmium ions, gold ions, cobalt ions, and zinc ions.
[0012] According to embodiments of the present invention, the nucleotide derivative includes one or more of nicotinamide mononucleotide, adenosine triphosphate, adenosine diphosphate, and adenosine monophosphate.
[0013] According to an embodiment of the present invention, the working concentration of the protein raw material is 10-50 mg / mL.
[0014] According to an embodiment of the present invention, the working concentration of the protease is 137–411 U / mL.
[0015] According to an embodiment of the present invention, the working concentration of the metal ion crosslinking agent is 50–250 mmol / L.
[0016] According to embodiments of the present invention, the working concentration of the nucleotide derivative is 0.5–8 mg / mL.
[0017] According to an embodiment of the present invention, the working concentration of the protein with self-assembly capability is 10–50 mg / mL.
[0018] According to an embodiment of the present invention, the working concentration of the nicotinamide mononucleotide is 0.5–8 mg / mL.
[0019] According to an embodiment of the present invention, the incubation treatment is carried out at a temperature of 25–50°C for a duration of 1–60 h.
[0020] In a second aspect, the present invention provides a carrier. According to an embodiment of the present invention, the carrier is prepared by the method described in the first aspect. The carrier according to the embodiment of the present invention can specifically target mitochondria and efficiently deliver nucleotide derivatives (such as nicotinamide mononucleotide) to mitochondria, significantly increasing their concentration in cellular mitochondria, thereby enhancing their biological function. In addition, the carrier also has good biocompatibility and stability, and has broad application prospects.
[0021] In a third aspect, the present invention provides an embedding body. According to an embodiment of the present invention, the embedding body comprises: the carrier described in the second aspect; and a loading material loaded on the carrier. The embedding body according to the embodiments of the present invention possesses good biocompatibility and stability, and can specifically target mitochondria and efficiently deliver nucleotide derivatives (such as nicotinamide mononucleotide) and bioactive components loaded thereon to the mitochondria, showing broad application prospects.
[0022] According to embodiments of the present invention, the above-mentioned embedding body may also have the following additional technical features:
[0023] According to an embodiment of the present invention, the loading material is a bioactive component.
[0024] According to embodiments of the present invention, the bioactive ingredient includes one or more of nutrients, antioxidants, diagnostic molecules, immunomodulators, and small molecule drugs.
[0025] In a fourth aspect, the present invention provides a cosmetic, health product, or pharmaceutical product. According to embodiments of the present invention, the cosmetic, health product, or pharmaceutical product comprises the carrier described in the second aspect and / or the embedding body described in the third aspect. The cosmetic, health product, or pharmaceutical product according to embodiments of the present invention, by comprising a carrier and / or embedding body specifically targeting mitochondria, can efficiently and specifically deliver nucleotide derivatives (such as nicotinamide mononucleotide) and other bioactive ingredients to mitochondria, thereby providing new ideas for product development in the fields of anti-aging, neurodegenerative diseases, and cardiovascular diseases.
[0026] In a fifth aspect, the invention proposes the use of the carrier described in the second aspect and / or the embedding body described in the third aspect in the preparation of a product. According to embodiments of the invention, the product has at least one of the following uses: prevention, relief, adjunctive treatment and / or treatment of mitochondrial dysfunction; antioxidant; regulation of mitochondrial function in cells; the embedding body contains nicotinamide mononucleotide; the product includes cosmetics, health products, or pharmaceuticals.
[0027] Those skilled in the art will understand that the features and advantages described above for the carrier and the embedding body are also applicable to this application, and will not be repeated here.
[0028] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Attached Figure Description
[0029] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which:
[0030] Figure 1 The figures shown are the characterization test results of NMN-NTs in Example 6 of this invention. A is the preparation flowchart of NMN-NTs. B, from left to right, are the TEM results of NTs, NMN-NTs-III (1 mg / mL) and NMN-NTs-I (4 mg / mL). C is the determination of NMN content that NTs can load at different NMN addition concentrations. D, from left to right, are the EDS results of NMN-NTs-I (4 mg / mL) (phosphorus and calcium elements). E is the heat curve between NMN and protein. F is the fitting curve of heat release and the molar ratio of NMN and BBs. G is the molecular docking result figure performed using AutoDock 4.2.
[0031] Figure 2The figures show the experimental results of the verification of the mitochondrial targeting mechanism of NMN-NTs in Example 7 of this invention. A is a confocal image of Cy5-labeled NTs and NMN-NTs co-localizing with mitochondria. B, from top to bottom, shows the analysis of the degree of co-localization of NTs (top) and NMN-NTs (bottom) with mitochondria. C, from left to right, shows the quantitative results of free isotope NMN and cells treated with isotope-labeled NMN-NTs in whole cells (left) and mitochondria (right). D, from left to right, shows the TEM results of cells treated with biotin-NTs (left) and biotin-NMN-NTs (right). E is the enrichment analysis of mitochondrial proteins bound to biotinylate beads using the gene ontology (GO) cellular component. F shows the identification of mitochondrial outer membrane (MOM) related proteins. The MOM-related proteins obtained by GO analysis were further cross-aligned with the MitoCarta 3.0 database. G represents the Western blot analysis of TOM40, VDAC1 / 2, BRI3BP and PAGM5 proteins adsorbed on biotin-modified magnetic beads and original magnetic beads.
[0032] Figure 3 Figure 8 shows the results of the in vivo biodistribution and absorption study of NMN-NTs in Example 8 of this invention. In Figure 8, A shows the retention of free Cy5, Cy5-labeled NTs and Cy5-labeled NMN-NTs in the gastrointestinal tract after 4 hours; B shows the retention of free Cy5, Cy5-labeled NTs and Cy5-labeled NMN-NTs in the gastrointestinal tract after 24 hours; C shows the absorption of free Cy5, Cy5-labeled NTs and Cy5-labeled NMN-NTs in the intestine; D shows the levels of isotope-labeled NMN (M5+) in plasma, jejunum, ileum, colon, liver and brain analyzed by LC / MS; and E shows the levels of isotope-labeled NAM in plasma, jejunum, ileum, colon, liver and brain analyzed by LC / MS.
[0033] Figure 4 This is a diagram showing the experimental results of the bioactivity verification of NMN-NTs in Example 9 of the present invention using a Parkinson's disease model. In the diagram, A is the flowchart of the construction and experiment of the mitochondrial injury animal model (MD); B is the duration of time the mice were on the rotarod during the rotarod experiment; and C is the effect of different treatments on NAD in the brains of MD model mice. + The following graphs show the effects of different treatments on the levels of NAD+ in the brains of MD model mice: D shows the effect of different treatments on superoxide dismutase (SOD) activity in the brains of MD model mice; E shows the effect of different treatments on malondialdehyde (MDA) levels in the brains of MD model mice; F shows the effect of different treatments on NAD+ levels in the colons of MD model mice; G shows the effect of different treatments on SOD activity in the colons of MD model mice; H shows the effect of different treatments on MDA levels in the colons of MD model mice; and I shows the effect of different treatments on NAD+ levels in the livers of MD model mice. +The results of the effects of different treatments on the SOD activity in the liver of MD model mice are shown in Figure J, and the results of the effects of different treatments on the MDA content in the liver of MD model mice are shown in Figure K.
[0034] Figure 5 This is a diagram showing the results of an anti-aging experiment on *C. elegans*, used in Example 10 of this invention to verify the bioactivity of NMN-NTs. A shows a confocal fluorescence image of mitochondria in *C. elegans* containing Cy5-labeled NMN-NTs. B, from left to right, shows the survival rates of wild-type (N2) and mitochondrial-damaged (wrn-1) nematodes, the effect of different treatments on the survival rate of N2, and the effect of different treatments on the survival rate of wrn-1. C shows the effect of different treatments on the number of body bends in the two types of nematodes. D shows the effect of different treatments on NAD+ levels in the two types of nematodes. + The results of the influence of content are shown in the confocal images and quantitative results of the effects of different treatments on the mitochondrial content in the two nematodes, from left to right. Detailed Implementation
[0035] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.
[0036] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this invention, unless otherwise stated, "a plurality of" means two or more.
[0037] The endpoints and any values of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of the various ranges, the endpoint values of the various ranges and individual point values, and individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.
[0038] In this document, the terms “comprising” or “including” are open-ended expressions, meaning they include the contents specified in this invention but do not exclude other aspects.
[0039] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.
[0040] In this document, the term "α-lac peptide" refers to a peptide obtained from α-lactalbumin by enzymatic hydrolysis or chemical methods, and in the embodiments of this invention, it refers to a peptide obtained by enzymatic hydrolysis using Bacillus licheniformis protease.
[0041] In this document, the term "nanotube" refers to a tubular structure with a diameter at the nanoscale, typically formed by the self-assembly or cross-linking of proteins, peptides, or other biomolecules. In the embodiments of this invention, it refers to a nanotube structure formed by the self-assembly of α-lactalbumin by the decomposition of α-lactalbumin into peptides under the action of a specific protease, Bacillus licheniformis protease, and then by the cross-linking action of the metal ion cross-linking agent calcium chloride.
[0042] These nanotubes possess a highly ordered structure and a large specific surface area, enabling them to effectively load and encapsulate bioactive substances such as nicotinamide mononucleotide (NMN). The nanotubes typically range in size from tens to hundreds of nanometers, a size range that allows them to interact with organelles such as mitochondria for highly efficient targeted delivery. Furthermore, the porosity and surface properties of the nanotubes can be optimized by adjusting the preparation conditions to meet diverse application requirements.
[0043] Methods for preparing carriers
[0044] This invention proposes a method for preparing a carrier. According to an embodiment of the invention, the method includes: S1: mixing protein raw materials, protease, metal ion cross-linking agent, and nucleotide derivative to obtain a mixed system; S2: incubating the mixed system, collecting the precipitate, and obtaining the carrier. The method of this invention, by mixing protein raw materials, protease, metal ion cross-linking agent, and nucleotide derivative (such as nicotinamide mononucleotide) and incubating them, thereby obtaining the carrier, has the advantages of simple preparation method, convenient operation, and easy large-scale production. The carrier prepared by this method can precisely target mitochondria, efficiently deliver nucleotide derivatives (such as nicotinamide mononucleotide), and has good biocompatibility and stability. It is also suitable for encapsulating various bioactive substances and has broad application prospects.
[0045] According to embodiments of the present invention, the protein raw material includes proteins with self-assembly capabilities. Thus, the protein raw material can spontaneously form an ordered structure in a mixed system using its inherent properties, providing a stable framework for the construction of the carrier, and allowing for the selection of different types of protein raw materials with self-assembly capabilities according to different needs and application scenarios.
[0046] According to embodiments of the present invention, the protein raw materials include one or more of α-lactalbumin, bovine serum albumin, soy protein, ovalbumin, ovalbumin, and lysozyme. Thus, different types of protein raw materials with self-assembly capabilities can be selected according to different needs and application scenarios. For example, the protein raw material is α-lactalbumin. α-lactalbumin itself has good self-assembly properties and biocompatibility, and can form stable nanostructures, providing a reliable framework for carrier construction. Furthermore, α-lactalbumin is easy to process and modify, has a wide range of sources, and is low in cost, making it suitable for large-scale production and application. In addition, α-lactalbumin itself also has certain bioactivity and can synergistically interact with other components such as metal ion crosslinking agents and proteases to further enhance the performance and function of the prepared carrier, giving it broad application prospects in biomedicine and other fields.
[0047] It should be noted that the protein raw materials include, but are not limited to, α-lactalbumin raw materials, bovine serum albumin raw materials, soy protein raw materials, ovotransferrin raw materials, ovalbumin raw materials, and lysozyme raw materials. Other protein raw materials known in the art with self-assembly capabilities are also covered within the scope of protection of this invention.
[0048] According to embodiments of the present invention, the protease includes one or more of Bacillus licheniformis protease, Bacillus subtilis protease A, trypsin, pepsin, and papain. Thus, different types of proteases can be flexibly selected according to different needs and application scenarios; exemplaryly, the protease is Bacillus licheniformis protease (BLP enzyme), which has high specificity and mild enzymatic hydrolysis conditions. While efficiently decomposing protein raw materials into peptides suitable for self-assembly, it can maintain the bioactivity and structural integrity of the peptides, thereby improving the safety, stability, and biocompatibility of the finally prepared carrier.
[0049] It should be noted that the proteases include, but are not limited to, Bacillus licheniformis protease, Bacillus subtilis protease A, trypsin, pepsin and papain, and other proteases known in the art with protein hydrolysis function are all covered within the scope of protection of this invention.
[0050] According to embodiments of the present invention, the metal ion crosslinking agent includes one or more of calcium ions, manganese ions, magnesium ions, nickel ions, cadmium ions, gold ions, cobalt ions, and zinc ions. Therefore, different types of metal ion crosslinking agents can be flexibly selected according to different needs and application scenarios. For example, the metal ion crosslinking agent is calcium chloride, which is easily soluble in aqueous solution and has mild crosslinking reaction conditions, without significantly affecting the bioactivity and structural integrity of the protein raw material. Calcium chloride, as a metal ion crosslinking agent, is present in the mixed system as calcium ions (Ca... 2+) form, calcium ions (Ca) play a role 2 + ) is widely present in organisms, exhibits low cytotoxicity and immunogenicity, and in addition, calcium ions (Ca) 2+ It can form stable ionic bonds with the carboxyl groups (-COOH) in protein raw materials, promoting the formation and stabilization of nanotube structures.
[0051] It should be noted that the metal ion crosslinking agent includes, but is not limited to, calcium ions, manganese ions, magnesium ions, nickel ions, cadmium ions, gold ions, cobalt ions, and zinc ions. Other metal ion crosslinking agents known in the art that have crosslinking promotion functions are all covered within the scope of protection of this invention.
[0052] According to embodiments of the present invention, the nucleotide derivative includes one or more of nicotinamide mononucleotide, adenosine triphosphate, adenosine diphosphate, and adenosine monophosphate. The introduction of the nucleotide derivative is closely related to the carrier's ability to target mitochondria; therefore, different types of nucleotide derivatives can be flexibly selected according to different needs and application scenarios. Exemplarily, the nucleotide derivative is nicotinamide mononucleotide, which serves as nicotinamide adenine dinucleotide (NAD). + Nicotinamide mononucleotide (NMN) is a direct precursor of NMN and plays an important role in key biological processes such as cellular energy metabolism, DNA repair, and mitochondrial function maintenance. The vector prepared by adding NMN to the mixture has the advantages of precise targeting of mitochondria, efficient delivery of NMN, high NAD+ conversion efficiency, good biocompatibility and stability, and is suitable for encapsulating a variety of bioactive substances, with broad application prospects.
[0053] According to embodiments of the present invention, the working concentration of the protein raw material is 10–50 mg / mL. Therefore, by controlling the working concentration of the protein raw material, the formation efficiency and structural stability of the carrier are further optimized, ensuring that the prepared carrier has good loading capacity and biocompatibility. Exemplarily, the working concentration of the protein raw material is 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, or 50 mg / mL, preferably 20–40 mg / mL, and more preferably 30 mg / mL.
[0054] According to embodiments of the present invention, the working concentration of the protease is 137–411 U / mL. Therefore, by controlling the working concentration of the protease, the degree of enzymatic hydrolysis of the protein raw material can be adjusted, thereby further optimizing the carrier formation efficiency, structural stability, and carrier performance. Exemplarily, the working concentration of the protease is 137 U / mL, 205.5 U / mL, 274 U / mL, 342.5 U / mL, or 411 U / mL, preferably 205.5–342.5 U / mL, and more preferably 274 U / mL.
[0055] According to an embodiment of the present invention, the working concentration of the metal ion crosslinking agent is 50–250 mmol / L. Thus, the structural properties of the support, such as porosity, are adjusted and optimized by controlling the working concentration of the metal ion crosslinking agent. Exemplarily, the working concentration of the metal ion crosslinking agent is 50 mmol / L, 100 mmol / L, 150 mmol / L, 200 mmol / L, or 250 mmol / L, preferably 100–200 mmol / L, and more preferably 150 mmol / L.
[0056] According to embodiments of the present invention, the working concentration of the nucleotide derivative is 0.5–8 mg / mL. Thus, by controlling the working concentration of the nucleotide derivative, the loading capacity of the carrier and the release efficiency of the loaded bioactive substance are further optimized; exemplaryly, the working concentration of the nucleotide derivative is 0.5 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, preferably 1–4 mg / mL, more preferably 2–4 mg / mL.
[0057] According to embodiments of the present invention, the working concentration of the self-assembling protein is 10–50 mg / mL. Thus, by controlling the working concentration of the self-assembling protein, the formation efficiency and structural stability of the carrier are further optimized and adjusted, ensuring that the carrier has good loading capacity and biocompatibility. Exemplarily, the working concentration of the self-assembling protein is 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, or 50 mg / mL, preferably 20–40 mg / mL, and more preferably 30 mg / mL.
[0058] According to embodiments of the present invention, the working concentration of the nicotinamide mononucleotide is 0.5–8 mg / mL. Thus, by controlling the working concentration of the nicotinamide mononucleotide, the loading capacity of the carrier and the release efficiency of the loaded bioactive substance are further optimized; exemplaryly, the working concentration of the nicotinamide mononucleotide is 0.5 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, preferably 1–4 mg / mL, more preferably 2–4 mg / mL.
[0059] According to an embodiment of the present invention, the incubation treatment temperature is 25–50°C, and the time is 1–60 h. Thus, by controlling the temperature and time of the incubation treatment, the formation efficiency and structural stability of the carrier are further optimized and adjusted. Exemplarily, the incubation treatment temperature is 25°C, 30°C, 35°C, 40°C, 45°C, or 50°C, preferably 30–45°C, more preferably 35°C; the incubation treatment time is 1 h, 5 h, 10 h, 20 h, 40 h, or 60 h, preferably 1–20 h, more preferably 1–5 h.
[0060] carrier
[0061] This invention proposes a carrier. According to an embodiment of the invention, the carrier is prepared by the aforementioned method. The carrier according to the embodiment of the invention can specifically target mitochondria and efficiently deliver nucleotide derivatives (such as nicotinamide mononucleotide) to mitochondria, significantly increasing their concentration in cellular mitochondria, thereby enhancing their biological function. In addition, the carrier also has good biocompatibility and stability, and has broad application prospects.
[0062] Embedded bodies
[0063] This invention proposes an embedding medium. According to an embodiment of the invention, the embedding medium comprises: the aforementioned carrier; and a loading material, wherein the loading material is loaded onto the carrier. The embedding medium according to the embodiment of the invention possesses good biocompatibility and stability, and can specifically target mitochondria and efficiently deliver nucleotide derivatives (such as nicotinamide mononucleotide) and bioactive components loaded thereon to the mitochondria, showing broad application prospects.
[0064] According to an embodiment of the present invention, the loading material is a bioactive component. Thus, the embedding body can load a variety of bioactive components and deliver them specifically and efficiently to the mitochondria.
[0065] According to embodiments of the present invention, the bioactive ingredient includes one or more of nutrients, antioxidants, diagnostic molecules, immunomodulators, and small molecule drugs. Therefore, different types of bioactive ingredients can be flexibly selected for loading according to different needs and application scenarios, thereby meeting different therapeutic or diagnostic requirements; for example, antioxidants such as vitamin C or vitamin E are selected for delivery to enhance cellular antioxidant capacity; diagnostic molecules such as fluorescent probes are selected for delivery for the diagnosis of related diseases.
[0066] Cosmetics, health products or medicines
[0067] This invention proposes a cosmetic, health product, or pharmaceutical. According to embodiments of the invention, the cosmetic, health product, or pharmaceutical includes the aforementioned carrier and / or the aforementioned embedding medium. The cosmetic, health product, or pharmaceutical according to embodiments of the invention, by including a carrier and / or embedding medium specifically targeting mitochondria, can efficiently and specifically deliver nucleotide derivatives (such as nicotinamide mononucleotide) and other bioactive ingredients to mitochondria, thereby providing new ideas for product development in the fields of anti-aging, neurodegenerative diseases, and cardiovascular diseases.
[0068] use
[0069] This invention proposes the use of the aforementioned carrier and / or the aforementioned embedding body in the preparation of products. According to embodiments of the invention, the product has at least one of the following uses: prevention, relief, adjunctive treatment and / or treatment of mitochondrial dysfunction; antioxidant; regulation of mitochondrial function in cells; the embedding body contains nicotinamide mononucleotide; the product includes cosmetics, health products, or pharmaceuticals.
[0070] Those skilled in the art will understand that the features and advantages described above for the carrier and the embedding body are also applicable to this application, and will not be repeated here.
[0071] The present invention will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.
[0072] Example 1: Preparation of NMN-NTs-I
[0073] 30 mg of purified α-lactalbumin was dissolved in 1 mL of PBS buffer (pH 7.4) and mixed well. Then, 20 μL of Bacillus licheniformis protease (BLP enzyme, 13.7 U / mg), 40 μL of CaCl2 (11.9 mg / mL), and 4 mg of nicotinamide mononucleotide (NMN) were added sequentially to obtain a mixture. The mixture was incubated in a 50 °C water bath for 60 min. To remove unassembled small molecules, the mixture was centrifuged at 13000 rpm for 10 min and washed twice with PBS to obtain the precipitate, which was the NMN-nanotube co-assembled system (NMN-NTs) sample. Finally, the obtained NMN-NTs sample was lyophilized and stored at -20 °C for later use.
[0074] Example 2: Preparation of NMN-NTs-II
[0075] The preparation method of NMN-NTs-II is the same as in Example 1, except that the amount of nicotinamide mononucleotide added is adjusted to 0.5 mg of nicotinamide mononucleotide.
[0076] Example 3: Preparation of NMN-NTs-III
[0077] The preparation method of NMN-NTs-III is the same as in Example 1, except that the amount of nicotinamide mononucleotide added is adjusted to 1 mg of nicotinamide mononucleotide.
[0078] Example 4: Preparation of NMN-NTs-IV
[0079] The preparation method of NMN-NTs-IV is the same as in Example 1, except that the amount of nicotinamide mononucleotide added is adjusted to 2 mg of nicotinamide mononucleotide.
[0080] Example 5: Preparation of NMN-NTs-V
[0081] The preparation method of NMN-NTs-V is the same as in Example 1, except that the amount of nicotinamide mononucleotide added is adjusted to 8 mg of nicotinamide mononucleotide.
[0082] Comparative Example 1: Preparation of NTs
[0083] The preparation method of NTs is the same as in Example 1, except that the amount of nicotinamide mononucleotide added is adjusted to not add nicotinamide mononucleotide.
[0084] Example 6: Characterization of NMN-NTs-I to V
[0085] 1. Size and morphological characterization
[0086] A small amount of NMN-NTs-I prepared in Example 1, NMN-NTs-III prepared in Example 3, and NTs freeze-dried samples prepared in Comparative Example 1 were dispersed in an appropriate amount of deionized water. The morphology of the nanotubes was observed and their size was measured using a transmission electron microscope (TEM).
[0087] 2. Measurement of load efficiency
[0088] A small amount of NMN-NTs-I to V lyophilized samples prepared in Examples 1 to 5 were taken, and the NMN loading efficiency of the NMN-NTs-I to V lyophilized samples was evaluated by ultra-high performance liquid chromatography (UPLC).
[0089] 3. Chemical composition analysis
[0090] A small number of NMN-NTs-I to V lyophilized samples prepared in Examples 1 to 5 were taken, and the chemical composition of the NMN-NTs-I to V lyophilized samples was characterized by transmission electron microscopy (TEM) combined with elemental distribution maps and energy dispersive spectroscopy (EDS) to confirm the spatial distribution characteristics of calcium (Ca) and phosphorus (P) elements in the nanotube structure.
[0091] 4. Interaction Analysis
[0092] A small amount of NMN-NTs-I to V lyophilized samples prepared in Examples 1 to 5 were taken, and the interaction between NMN and α-lac peptide was investigated by isothermal titration calorimetry (ITC).
[0093] 5. Molecular docking simulation
[0094] Molecular docking simulations of NMN with four BLP-digested peptides were performed using AutoDock 4.2 to reveal key binding residues. The four BLP-digested peptides were obtained through preparative liquid chromatography separation, and their specific sequences are as follows:
[0095] α-lac peptide 1 sequence:
[0096] LKDLKGYGVSLPEWVCTTFHTSGYDTQAIVQNNDSTEYGLFQINNKIWCKDDQNP HSSNICNISCDKFLDDDLTDDIMCVKKILDKVGINYWLAHKALCS(SEQ ID NO:1)
[0097] α-lac peptide 2 sequence:
[0098] WVCTTFHTSGYDTQAIVQNNDSTEYGLFQINNKIWCKDDQNPHSSNICNISCDKFLDDDLTDDIMCVKKILDKVGINYWLAHKALCSE(SEQ ID NO:2)
[0099] α-lac peptide 3 sequence:
[0100] LKDLKGYGVSLPEWVCTTFHTSGYDTQAIVQNNYGLFQINNKIWCKDDQNPHSSNICNISCDKFLDDDLTDDIMCVKKILDKVGINYWLAHKALCS(SEQ ID NO:3)
[0101] α-lac peptide 4 sequence:
[0102] LKDLKGYGVSLPEWVCTTFHTSGYYGLFQINNKIWCKDDQNPHSSNICNISCDKFLDDDLTDDIMCVKKILDKVGINYWLAHKALCS(SEQ ID NO:4)
[0103] The relevant characterization test results of NMN-NTs are shown in [link to data]. Figure 1 .
[0104] The results showed that, using this method, NMN was introduced into the α-lactoglobulin peptide (α-lac peptide) containing BLP hydrolyzed protein and Ca during the early stages of nanotube (NT) formation. 2+ In the mixed system (see details) Figure 1 (A) When the NMN concentration is 1 mg / mL, its co-assembly efficiency with NTs is significantly improved. When the initial NMN concentration is 4 mg / mL, the NMN loading efficiency reaches its maximum value, and the nanotube size decreases from 581.4 ± 96.76 nm to 337.7 ± 46.86 nm (see section A for details). Figure 1 (B to C in the text); Furthermore, the spatial distribution characteristics of calcium (Ca) and phosphorus (P) elements in the nanotube structure (especially the detection of P) confirm the efficient co-assembly of NMN and nanotubes (see details). Figure 1 In addition, based on the fitting curve of the reaction heat as a function of the molar ratio of α-lac peptide to NMN, its optimal fit is a "two-site binding" model, with high-affinity binding constants Ka1 and Ka2 being 5.38 × 10⁻⁶. 5 and 1.81×10 4 ( Figure 1 E-1F); among them, α-lac peptide 3 exhibits the strongest binding energy (-5.65 kcal / mol), and the binding sites mainly involve aspartic acid residues (Asp84), lysine residues (Lys85), and asparagine residues (Asn83) of α-lac peptide 3, forming a stable hydrogen bond network and hydrophobic interaction interface, further confirming that the binding mechanism of NMN to the α-lac peptide is synergistically driven by strong hydrophobic interactions and moderate hydrogen bonding (see details). Figure 1 (G).
[0105] Example 7: Validation of the mitochondrial targeting mechanism of NMN-NTs
[0106] 1. Preparation of Cy5-labeled NTs and NMN-NTs
[0107] The preparation method of Cy5-labeled NTs is the same as that of Comparative Example 1, except that after the NTs sample is prepared, 1 μL of Cy5 is added to the solution, incubated overnight at 4°C, centrifuged at 12000 rpm for 5 min and the supernatant is removed. This process is repeated 5 times to remove free Cy5 and obtain Cy5-labeled NTs. The concentration of Cy5-labeled NTs is then determined by BCA protein quantification method.
[0108] The preparation method of Cy5-labeled NMN-NTs is the same as in Example 1, except that after the NMN-NTs sample is prepared, 1 μL of Cy5 is added to the solution, incubated overnight at 4°C, centrifuged at 12000 rpm for 5 min and the supernatant is removed. This process is repeated 5 times to remove free Cy5 and obtain Cy5-labeled NMN-NTs. The concentration of Cy5-labeled NMN-NTs is then determined by BCA protein quantification.
[0109] 2. Preparation of isotope-labeled NMN and NMN-NTs
[0110] The preparation of isotope-labeled NMN involves three steps: preparation 13 C-labeled riboflavin tetraacetate and 18 O-labeled nicotinamide; 13 C 18 Synthesis of O-labeled nicotinamide nucleoside; and using 18 O-labeled H2O is phosphorylated to produce NMN (M5+).
[0111] The preparation method of isotope-labeled NMN-NTs is the same as in Example 1, except that the isotope-labeled NMN is prepared according to the above method during the sample preparation process.
[0112] 3. Preparation of Biotin-NTs and Biotin-NMN-NTs
[0113] Preparation of Biotin-NTs:
[0114] 1 mg / mL of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide were dissolved in PBS buffer, respectively. Then, 2 mg / mL of biotin was added, and the mixture was rotated at 4 °C for 4 h to activate the carboxyl group of biotin, thus obtaining an activated biotin solution. Subsequently, 0.5 mL of the NTs (30 mg / mL) prepared in Comparative Example 1 was mixed with 1.5 mL of the activated biotin solution and rotated at 4 °C overnight. The biotin-NTs were collected by centrifugation at 12000 rpm the next day.
[0115] Preparation of Biotin-NMN-NTs:
[0116] 1 mg / mL of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide were dissolved separately in PBS buffer. Then, 2 mg / mL of biotin was added to the mixture, and the mixture was rotated at 4°C for 4 hours to activate the carboxyl group of biotin. Subsequently, 0.5 mL of the NMN-NTs (30 mg / mL) prepared in Example 1 was mixed with 1.5 mL of the activated biotin solution and rotated overnight at 4°C. The next day, the mixture was centrifuged at 12000 rpm to collect biotin-NMN-NTs.
[0117] 4. Cell experiments
[0118] The Cy5-labeled NTs and Cy5-labeled NMN-NTs obtained in step 1 were co-incubated with NIH3T3 cells (purchased from Peking Union Medical College, concentration of 200,000 cells / well) at 200 μg / mL for 4 h, and their co-localization with mitochondria was observed using confocal microscopy.
[0119] The isotope-labeled NMN and isotope-labeled NMN-NTs obtained in step 2 were co-incubated with NIH3T3 cells (concentration of 200,000 cells / well) at 200 μg / mL for 4 h, and then analyzed by liquid chromatography / mass spectrometry.
[0120] 5. Biotinylated magnetic bead capture experiment
[0121] The biotin-NTs and biotin-NMN-NTs obtained in step 3 were co-incubated with NIH3T3 cells (concentration of 5 million cells / well) at 200 μg / mL for 4 h. Mitochondrial proteins adsorbed on the biotin-modified biotin-NTs or biotin-NMN-NTs were then captured using biotin magnetic beads. Subsequent analysis included LC / MS, Gene Ontology (GO) analysis (classifying proteins by mitochondrial sublocalization based on a cell component database), and Western blot. The control group for Western blot consisted of blank magnetic beads, and the α-lac protein group consisted of:
[0122] WVCTTTFHTSGYDTQAIVQNNDSTEYGLFQINNKIWCKDDQNPHSSNICNISCDKFLDDDLTDDIMCVKKILDKVGINYWLAHKALCSE (SEQ ID NO: 2).
[0123] The experimental results verifying the mitochondrial targeting mechanism of NMN-NTs are shown in [link to experimental results]. Figure 2 .
[0124] The results showed that Cy5-labeled NTs had low co-localization with mitochondria, while the co-localization efficiency of Cy5-labeled NMN-NTs obtained by co-assembling with NMN was significantly improved (see details). Figure 2 (A-B in the text); Cy5-labeled NMN-NTs can effectively deliver NMN to the mitochondria of NIH3T3 cells and further convert it into NAD+ (p<0.05, see details). Figure 2 (C) Of all mitochondrial proteins, 37 were identified as being located in the outer mitochondrial membrane (MOM), of which 20 showed cross-references between GO analysis and the MitoCarta 3.0 database (see details). Figure 2 In addition, among MOM-related proteins, TOM40 and VDAC1 / 2 were detected in biotin-modified biotin-NTs and biotin-NMN-NTs; BRi3-binding protein (BRI3BP) and phosphoglycerate mutase family member 5 (PGAM5) specifically adsorbed onto biotin-NMN-NTs; Western blot further confirmed the results of these key proteins. Compared with BLP-cleaved α-lac peptides and blank magnetic beads, biotin-modified biotin-NTs and biotin-NMN-NTs significantly increased the adsorption of TOM40, VDAC1 / 2, BRI3BP, and PGAM5, indicating that the nanotube structure can enhance mitochondrial targeting ability; more importantly, compared with NTs, NMN-NTs showed a stronger interaction with MOM proteins (see [link to details]). Figure 2 (G in the middle).
[0125] The above results demonstrate that NMN-NTs can achieve efficient mitochondrial targeting and NMN delivery by specifically binding to key proteins of the mitochondrial outer membrane (such as TOM40, VDAC1 / 2, BRI3BP, and PGAM5). Their structural optimization and molecular interaction mechanism lay an important foundation for the development of nanotools that precisely target mitochondria.
[0126] Example 8: Study on the biodistribution and absorption of NMN-NTs in vivo
[0127] 1. Animal experiments with Cy5-labeled NMN-NTs
[0128] Male C57BL / 6N mice were randomly divided into Cy5 group, NTs group, and NMN-NTs group. Each group of mice was given equal amounts of free Cy5 (Cy5 group), Cy5-labeled NTs prepared in Example 7 (NTs group), and Cy5-labeled NMN-NTs prepared in Example 7 (NMN-NTs group) via enteric-coated capsules orally. The distribution of Cy5-labeled NMN-NTs in the gastrointestinal tract was observed using an animal in vivo imaging system at 4 h and 24 h after oral administration.
[0129] 2. Tissue absorption analysis
[0130] Four hours after oral administration of the enteric-coated capsules in step 1, mice in each group were sacrificed, and jejunal, ileal, and colonic tissues were collected. The absorption of Cy5-labeled NMN-NTs in intestinal epithelial cells was observed using confocal laser scanning microscopy (CLSM).
[0131] 3. Animal experiments with isotope-labeled NMN-NTs
[0132] Male C57BL / 6N mice were randomly divided into an NMN group (free NMN group) and an NMN-NTs group (nanotube delivery group). Each group of mice was given an equal amount of isotopically labeled NMN (NMN group) prepared in Example 7 and isotopically labeled NMN-NTs (NMN-NTs group) prepared in Example 7. Plasma, jejunum, ileum, colon, liver, and brain tissue were collected from each group of mice 0.5 h, 1 h, and 4 h after administration. Nicotinamide (NAM) is a byproduct of NAD+ consumption (such as that produced by enzyme catalytic activity of sirtuins, PARPs, etc.). NMN administered to the mice can be rapidly converted into NAD+, and then generate isotopically labeled NAM. The content of isotopically labeled NMN (M5+) was quantitatively analyzed by liquid chromatography / mass spectrometry (LC / MS).
[0133] The experimental results of the study on the biodistribution and absorption of NMN-NTs in vivo are shown in [link to experimental results]. Figure 3 .
[0134] The results showed that, compared with free Cy5, Cy5-labeled NTs and Cy5-labeled NMN-NTs exhibited higher fluorescence signals and longer retention times in the gastrointestinal tract (see details). Figure 3 (A-B in the text) This experimental result can be attributed to the highly efficient mucus-penetrating ability of α-lac peptide nanotubes; confocal laser scanning microscopy revealed that the red-labeled NMN-NTs were detected in the epithelial cells of the small intestine (including the jejunum and ileum) (yellow arrows), and a small amount of nanotubes were also observed in the colon (see details). Figure 3 In the nanotube delivery group, the NMN content in the jejunum was significantly reduced at 0.5 h after administration (p<0.001); and the NMN (M5+) content in the ileum (p<0.001) and colon (p<0.05) was effectively increased 1 h after administration. Figure 3D); In the nanotube delivery group, plasma isotope-labeled NAM levels significantly increased at 1 h (p<0.001) and 4 h (p<0.01). Notably, the isotope-labeled NAM content in the colon tissue of the nanotube delivery group showed a gradual accumulation trend within 4 h and remained higher than that in the free NMN administration group. Furthermore, the heavy isotope NAM content in the liver and brain tissue of the nanotube delivery group increased significantly only after 0.5 h, suggesting that compared to free NMN, the nanotube delivery system (NMN-NTs) can achieve rapid NMN entry into systemic circulation and efficient integration into the NAD+ metabolic cycle (see details). Figure 3 (E in the text)
[0135] The above results indicate that after oral administration, the nanotube delivery system NMN-NTs is mainly absorbed in ileal epithelial cells, and the nanotube delivery system NMN-NTs significantly optimizes the intestinal absorption efficiency of NMN. In addition, the nanotube delivery system NMN-NTs can not only protect NMN from degradation in the gastrointestinal environment, but also significantly improve its delivery efficiency in key target organs (such as the liver and brain), providing strong support for its potential in biomedical applications.
[0136] Example 9: Validation of the bioactivity of NMN-NTs - Parkinson's disease model experiment
[0137] Rotenone induces Parkinson's disease by inhibiting mitochondrial complex I, triggering oxidative stress, and selectively damaging dopaminergic neurons, particularly in the substantia nigra. A rotenone-induced mitochondrial damage-induced Parkinson's disease-like animal model was established using C57BL / 6N mice. The specific experimental steps are as follows:
[0138] Experimental mice were randomly divided into four groups: control group (NC group), Parkinson's disease model group (MD group), Parkinson's disease model-NTs treatment group (MD+NTs group), Parkinson's disease model-free NMN treatment group (MD+NMN group), and Parkinson's disease model-NMN-NTs treatment group (MD+NMN-NTs group). Each group was administered an equal volume (100 μL) of enteric-coated capsules containing PBS (NC group), PBS-containing enteric-coated capsules (MD group), NTs prepared in Comparative Example 1 (MD+NTs group), free NMN (MD+NMN group), and NMN prepared in Example 1, respectively. Mice in the MD, MD+NMN-NTs, MD+NMN, and MD+NMN-NTs groups were intraperitoneally injected with 3 mg / kg rotenone after three weeks of continuous induction. Meanwhile, mice in the NC group were intraperitoneally injected with corn oil (rotenone solvent) (200 μL). Intraperitoneal injection continued for three weeks. After three weeks of rotenone induction, plasma, colon, liver, and brain tissues of the mice were collected. The NAD+ level in the tissues was analyzed by liquid chromatography / mass spectrometry (LC / MS), and the level of oxidative stress was assessed by superoxide dismutase (SOD) activity and malondialdehyde (MDA) content.
[0139] Bioactivity verification of NMN-NTs - Experimental results in a Parkinson's disease model are shown below. Figure 4 .
[0140] The results showed that rotenone-induced oxidative stress was manifested in the colon, liver and brain as decreased superoxide dismutase (SOD) activity and increased malondialdehyde (MDA) content, while oral administration of enteric-coated NMN-NTs significantly alleviated this phenomenon; in addition, the NAD+ levels in the colon, liver and brain of mice in the MD+NMN-NTs group were significantly higher than those in the MD+NMN group.
[0141] The above results demonstrate that NMN-NTs can not only effectively alleviate rotenone-induced oxidative stress, but also significantly increase NAD+ levels in key tissues, providing strong support for their potential application in the treatment of Parkinson's disease.
[0142] Example 10: Validation of the bioactivity of NMN-NTs - Anti-aging experiment
[0143] The anti-aging potential of NMN-NTs was verified using *C. elegans*. The NGM culture medium death method was employed to maximize the absorption efficiency of NMN-NTs prepared in Example 1 by the nematodes. Furthermore, to investigate whether the NMN-NTs prepared in Example 1 co-localized with mitochondria in the nematodes, *wrn-1* nematodes with mitochondrial dysfunction and wild-type N2 nematodes were continuously incubated with MitoTracker Green fluorescent tracer for 24 hours to label the mitochondria. The incubated *wrn-1* and N2 nematodes were then randomly divided into a control group, an NTs group, an NMN group, and an NMN-NTs group, and each nematode was exposed to ordinary NGM culture plates (according to the literature "Wang Yanju, Ma Jianwei, Wang Xizhuo, et al. Effects of grape seed proanthocyanidins on the anti-aging of *C. elegans* [J]. Food Industry Technology, 2014, 35(20): The samples were treated for 24 h with the experimental methods described in “369-373” (Control group), ordinary NGM culture plate + Cy5-labeled NTs prepared in Example 7 (NTs group), NGM culture plate + Cy5-labeled NMN (NMN group), and NGM culture plate + Cy5-labeled NMN-NTs prepared in Example 7 (NMN-NTs group); then, the colocalization of Cy5-labeled NTs, NMN, or NMN-NTs with MitoTracker Green-labeled mitochondria was observed by fluorescence microscopy or other imaging techniques. If both emitted fluorescence signals at the same location in the cell, it indicated that they were colocalized with mitochondria.
[0144] Bioactivity verification of NMN-NTs - Results of the Caenorhabditis elegans anti-aging experiment are shown below. Figure 5 .
[0145] The results showed that Cy5-labeled NMN-NTs could co-localize with nematode mitochondria (P = 0.697, see details). Figure 5 Mitochondrial dysfunction significantly shortened the median lifespan of nematodes (N2 nematodes: 20 days; wrn-1 nematodes: 16 days; p<0.001). Treatment with Cy5-labeled NMN-NTs prolonged the median lifespan of both N2 and wrn-1 nematodes to 22 days (p<0.001). Notably, the maximum lifespan of wrn-1 nematodes treated with Cy5-labeled NMN-NTs was significantly extended to 26 days compared to the Control group (24 days) (p<0.001). Furthermore, in wrn-1 nematodes, treatment with Cy5-labeled NMN-NTs showed a more significant therapeutic effect in prolonging lifespan compared to Cy5-labeled free NMN (p<0.001, see details). Figure 5Further research revealed that Cy5-labeled NMN-NTs treatment induced lifespan extension in wild-type N2 nematodes (p<0.01) and mitochondrial-dysfunctional wrn-1 nematodes (p<0.001), accompanied by improved health duration. This improvement was quantified by the number of body bends on a sterile agar plate within 30 seconds (see section B for details). Figure 5 In section C), it is noteworthy that NAD+ levels in the wrn-1 nematode with mitochondrial dysfunction were significantly lower than those in the wild-type N2 nematode (p<0.05, see details). Figure 5 (D) Consistent with lifespan and health period data, Cy5-labeled NMN-NTs treatment significantly increased the total NAD+ levels in N2 (p<0.05) and wrn-1 (p<0.01) nematodes; Cy5-labeled NMN-NTs feeding treatment effectively reduced the mitochondrial content in N2 and wrn-1 nematodes (p<0.001); furthermore, the nanotube delivery system (NMN-NTs) facilitated the effective alleviation of mitochondrial dysfunction in N2 (p<0.01) and wrn-1 (p<0.001) nematodes by NMN (p<0.001, see details). Figure 5 (E in the text)
[0146] The above results demonstrate that NMN-NTs, this innovative mitochondrial targeted delivery system, significantly overcomes the limitations of free NMN and efficiently enhances NAD through precise co-localization of mitochondria. + At the level of mitochondrial dysfunction, under the pathological background of mitochondrial compensatory hyperplasia in the wrn-1 nematode, it not only powerfully reverses mitochondrial dysfunction, but also achieves a breakthrough in lifespan and health period extension with the advantages of the carrier, highlighting the synergistic mechanism and precise repair potential of targeted delivery in anti-aging intervention.
[0147] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.
[0148] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.
Claims
1. A method for preparing a carrier, characterized in that, include: S1: The protein raw materials, protease, metal ion cross-linking agent and nucleotide derivative are mixed to obtain a mixed system; S2: The mixed system is incubated and the precipitate is collected to obtain the carrier.
2. The method according to claim 1, characterized in that, The protein raw materials include proteins with self-assembly capabilities; Optionally, the protein raw materials include one or more of α-lactalbumin raw materials, bovine serum albumin raw materials, soy protein raw materials, ovotransferrin raw materials, ovalbumin raw materials, and lysozyme raw materials; Optionally, the protease includes one or more of Bacillus licheniformis protease, Bacillus subtilis protease A, trypsin, pepsin, and papain; Optionally, the metal ion crosslinking agent includes one or more of calcium ions, manganese ions, magnesium ions, nickel ions, cadmium ions, gold ions, cobalt ions, and zinc ions; Optionally, the nucleotide derivative includes one or more of nicotinamide mononucleotide, adenosine triphosphate, adenosine diphosphate, and adenosine monophosphate.
3. The method according to claim 1, characterized in that, The working concentration of the protein raw material is 10–50 mg / mL. Optionally, the working concentration of the protease is 137–411 U / mL; Optionally, the working concentration of the metal ion crosslinking agent is 50–250 mmol / L; Optionally, the working concentration of the nucleotide derivative is 0.5–8 mg / mL.
4. The method according to claim 2, characterized in that, The working concentration of the protein with self-assembly capability is 10–50 mg / mL; Optionally, the working concentration of the nicotinamide mononucleotide is 0.5–8 mg / mL.
5. The method according to claim 1, characterized in that, The incubation treatment is carried out at a temperature of 25–50°C for a duration of 1–60 hours.
6. A carrier, characterized in that, The carrier is prepared by the method described in any one of claims 1 to 5.
7. An embedding body, characterized in that, include: The carrier as described in claim 6; A load, which is loaded onto the carrier.
8. The embedding body according to claim 7, characterized in that, The loading material is a bioactive component; Optionally, the bioactive ingredient includes one or more of nutrients, antioxidants, diagnostic molecules, immunomodulators, and small molecule drugs.
9. A cosmetic, health product, or pharmaceutical product, characterized in that, It includes the carrier as described in claim 6 and / or the embedding body as described in claim 7 or 8.
10. The use of the carrier according to claim 6 and / or the embedding body according to claim 7 or 8 in the preparation of a product, characterized in that, The product has at least one of the following uses: Prevention, mitigation, adjunctive therapy, and / or treatment of mitochondrial dysfunction; Antioxidant; Regulates mitochondrial function in cells; The embedding body contains nicotinamide mononucleotide; The products include cosmetics, health products, or pharmaceuticals.
